Thanks to cnsi for press release hard copies,
shareholders should be getting them in the mail
about now. Reading these over once again, here
were some highlights.
From the Nov 29th, 1999 PR:
GGF2, 14 patents and 54 pending, gee, I think
they have that growth factor covered.
From the Dec 14th, 1999 PR:
More patents, "The claims covered by these
patents provide additional support for cnsi's
collaboration with Allergan in the discovery of
novel vision-sparing treatments for glaucoma,
and should also benefit the Company's efforts
to discover and develop treatments for chronic
pain, stroke, traumatic brain injury, and
Parkinson's disease"
Extension of Allergan collaboration came on Dec 6th, 1999.
Takes them to Nov 2000 with 1.25m research support plus
potential milestones up to 16m and royalties.
The Jan 4th, 2000 PR speaks of 5161 with Algos and Endo,
maybe this has something to do with what Yukon said,
but matters not, cnsi seems cheap and well managed and
that is good enough for me. And look ma--no trades! |
